



HAL
open science

**Novel, tightly structurally related
N-myristoyltransferase inhibitors display equally potent
yet distinct inhibitory mechanisms**

Frédéric Rivière, Cyril Dian, Rémi Dutheil, Paul Monassa, Carmela Giglione,
Thierry Meinel

► **To cite this version:**

Frédéric Rivière, Cyril Dian, Rémi Dutheil, Paul Monassa, Carmela Giglione, et al.. Novel, tightly structurally related N-myristoyltransferase inhibitors display equally potent yet distinct inhibitory mechanisms. *Structure*, 2024, 32 (10), pp.1737-1750.e3. 10.1016/j.str.2024.08.001 . hal-04744994

HAL Id: hal-04744994

<https://hal.science/hal-04744994v1>

Submitted on 19 Oct 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1
2
3 **Novel, tightly structurally-related N-myristoyltransferase inhibitors display**
4 **equally potent yet distinct inhibitory mechanisms**

5 Frédéric Rivière^{iD,a}, Cyril Dian^{iD,a}, Rémi F. Dutheil^{iD,a}, Paul Monassa^{iD,a}, Carmela
6 Giglione^{iD,@,a,*}, Thierry Meinnel^{iD,@,a,**}
7
8
9

10
11
12 ^a Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC),
13 91198 Gif-sur-Yvette, France
14
15
16
17
18
19

20 **Running title:** Novel NMT inhibition mechanisms
21
22
23

24 ^{iD} ORCID 0000-0001-6366-1904 (F. Rivière); 0000-0002-6349-3901 (C. Dian); 0000-0002-
25 2910-6648 (R.F. Dutheil); 0000-0003-4713-8069 (P. Monassa); 0000-0002-7475-1558 (C.
26 Giglione); 0000-0001-5642-8637 (T. Meinnel)
27
28
29 @twitter @giglionelab (C. Giglione); @meinnel (T. Meinnel)
30
31
32

33 ^{*,**} Corresponding authors; correspondence to thierry.meinnel@i2bc.paris-saclay.fr (lead
34 contact) or carmela.giglione@i2bc.paris-saclay.fr
35
36
37
38
39
40
41
42

43 **Keywords:** acylation; lysine; myristoylation; *N*-myristoyltransferase; N-terminal modification
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Summary

1
2
3 N-myristoyltransferases (NMTs) catalyze essential acylations of N-terminal alpha or epsilon
4 amino groups of glycines or lysines. Here, we reveal that peptides tightly fitting the optimal
5 glycine recognition pattern of human NMTs are potent prodrugs relying on a single-turnover
6 mechanism. Sequence scanning of the inhibitory potency of the series closely reflects NMT
7 glycine substrate specificity rules, with the lead inhibitor blocking myristoylation by NMTs of
8 various species. We further redesigned the series based on the recently recognized lysine-
9 myristoylation mechanism by taking advantage of (i) the optimal peptide chassis and (ii) lysine
10 side chain mimicry with unnatural enantiomers. Unlike the lead series, the inhibitory properties
11 of the new compounds rely on the protonated state of the side chain amine, which stabilizes a
12 salt bridge with the catalytic base at the active site. Our study provides the basis for designing
13 first-in-class NMT inhibitors tailored for infectious diseases and alternative active site
14 targeting.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Introduction

1
2
3 N-myristoyltransferase (NMT) is an essential enzyme in all eukaryotes that ensures protein
4 myristoylation, a major lipid modification ^{1,2}. Myristoylation usually involves direct ligation
5 of a C:14:0 to the free amino group of N-terminal glycine residues (Gly-myristoylation). NMT
6 has also been shown to mediate lysine myristoylation (Lys-myristoylation) ^{3,4}. Lys-
7 myristoylation appears to be a rare NMT-driven acylation in humans, and whether it occurs in
8 other organisms is unknown ⁵. The lipid donor to NMT is myristoyl coenzyme A (Myr-CoA),
9 and its prior binding is required for the polypeptide substrate to be further properly recognized
10 and then acylated. Release of the products marks the final and limiting step of the reaction ^{6,7}
11 caused by conformational change and dissociation of CoA. As a result, the myristoylated
12 peptide product is made solvent accessible and fast released from NMT. Due to its poor affinity
13 to NMT and competition with Myr-CoA, a much higher affinity ligand, the Myr-peptide cannot
14 bind again and this ensures enzyme turnover ⁷⁻¹⁰.

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32 Most Gly-myristoylation targets play indispensable roles in cellular communication,
33 linking cell membranes to extracellular signals and facilitating secretory and endolytic
34 pathways ². As such, characterizing the complete set of myristoylated proteins of an organism,
35 its myristoylome, is therefore a long-time goal in the field. Recently, click chemistry
36 approaches have been used to characterize the myristoylome based on myristate mimicking
37 clickable analogs. Such compounds, provided that they are imported into target cells, allow
38 significant enrichment and further characterization of the associated protein (for a review, see
39 ²). While such analyses can be performed in different organisms and have revealed several
40 unexpected myristoylated proteins ¹¹⁻¹⁵, the click-based approach is still not powerful enough
41 to allow full description of all myristoylated NMT substrates. In addition, false positives may
42 arise through related metabolic pathways ², mandating the use of NMT inhibitors to validate
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 the targets identified by click-chemistry ¹². Therefore, nowadays there is still a gap between
2 the expected protein content of an organism and that delivered by even the most sophisticated
3 approaches ^{2,15,16}.
4
5
6

7 NMT targets are also retrieved from many viral proteomes ². Following particle entry,
8 eukaryotic viruses hijack the protein expression machinery to take advantage of cellular NMT
9 activity, as demonstrated for retroviruses including HIV ^{2,17}. NMT inhibitors have shown
10 efficacy against various viruses including the common cold, polio, and foot-and-mouth viruses
11 without host cell toxicity ¹⁸. More recently, NMT inhibitors were also demonstrated to generate
12 non-infectious particles of SARS-CoV-2 and poxviruses including vaccinia and monkeypox
13 viruses ^{19,20}. In addition to their use as therapeutics in cancer such as lymphoma ^{21,22}, malaria,
14 and sleeping sickness ^{11,23-26}, NMT inhibitors could therefore be useful in other infections
15 including fungal diseases ²⁷⁻²⁹.
16
17
18
19
20
21
22
23
24
25
26
27
28

29 This study emerged from the observation that an N-terminal glycine-starting peptide
30 extracted from a likely NMT target acts as an inhibitor rather than a substrate *in vitro*. We
31 studied the myristoylation inhibition rules guided by Gly-peptide mimics. This knowledge was
32 used to design Lys-myristoylation-based inhibitors. In both cases, structural and dedicated
33 kinetic analyses revealed the atomic basis of the inhibitory mechanism. Gly-myristoylation
34 inhibition involves product inhibition and single turnover, while Lys-myristoylation inhibition
35 involves a distinct limiting deprotonation step. Finally, armed with our new series of inhibitors,
36 we reveal similar efficacy with a variety of NMTs including those from humans, plants, fungi,
37 and apicomplexa.
38
39
40
41
42
43
44
45
46
47
48
49
50

51 **Results**

52 **Peptides displaying the major recognition motifs are not substrates and behave as tight**

53 **HsNMT1 inhibitors**

1 We previously reported the very detailed characterization of the substrate specificity of human
2 NMT1 (HsNMT1) for Gly-myristoylation, proposing a canonical optimal substrate logo
3
4 $G_2[\underline{NCAQ}][\underline{CASV}][\underline{FLC}]\underline{S}[\underline{KRC}]P[\underline{SR}]$ ³⁰. The sequence that takes each of the most likely
5 residues occurring at a given position of the logo into account corresponds to $G_2NCFSKPR$,
6
7 herein referred to as the “reference” sequence. Surprisingly, there was no evidence of the
8
9 release of myristoylated products of the synthetic peptide displaying the reference sequence
10
11 upon catalysis by HsNMT1 *in vitro* even at extremely low detection limits ($10^{-1} M^{-1} s^{-1}$; **Fig.**
12
13 **1a** dotted line). We previously discovered that the first six residues are recognized by dedicated
14
15 pockets (pockets 2-7) of the active site deep crevice of HsNMT1 ¹. The reference sequence
16
17 closely resembles the N-terminus of human apoptosis-inducing factor mitochondria-associated
18
19 3 protein (AIFM3; Q96NN9, $G_2\underline{GCFSKPK}$), differing mainly in the Gly at position 3 instead
20
21 of Asn. Human AIFM3 is known to be myristoylated, as is the corresponding derived
22
23 octapeptide *in vitro* ^{30,31}. In previous reports ^{30,32}, we also observed that the catalytic efficiencies
24
25 of hundreds of octapeptides derived from genuine substrates range over four orders of
26
27 magnitude *in vitro* (from 10^1 to $10^5 M^{-1}s^{-1}$). When comparing the most to the least efficient
28
29 substrates, we obtained the consensus sequence $G_2C[CS][\underline{FLT}]\underline{SKI}[\underline{RFD}]$ (**Fig. S1**), which was
30
31 almost superimposable over the reference peptide. Unexpectedly, this sequence lacked the Asn
32
33 at position 3, like in AIFM3, so we searched for human protein N-termini with the closest
34
35 similarity to the reference sequence, retrieving only one such sequence - GNLLSKFR - derived
36
37 from human nuclear pore-associated protein 1 (NPAP1; Q9NZP6), a primate-specific protein
38
39 ³³. We unexpectedly noticed that the NPAP1-derived octapeptide was not a substrate of either
40
41 HsNMT1 or HsNMT2 ³⁰ (**Table S1**), similar to the reference peptide.
42
43
44
45
46
47
48
49
50
51
52

53 We next determined the 3D structure of the complex of the reference peptide with
54
55 HsNMT1 in the presence of Myr-CoA. This peptide substrate was modified into a product, i.e.,
56
57
58
59
60
61
62
63
64
65

1 myristoylated, when trapped into crystalline HsNMT1 (**Fig. 2a; Fig. S2a**). There was
2 remarkable optimization of the fit of the side chains into major pockets 3 to 6 (**Fig. 2a-c**). The
3 reference peptide proved to be a potent inhibitor, with an IC_{50} of the order of the HsNMT1
4 concentration used in the assay, indicative of a strong binding constant in the sub-micromolar
5 range (**Fig. 1a,b; Table S1**). As an alternative measurement of the binding constant of the
6 reference peptide, we performed microcalorimetry experiments using isothermal titration
7 calorimetry (ITC), measuring a dissociation constant (K_D) of 9 ± 6 nM for the reference peptide
8 when HsNMT1 was pre-incubated in the presence of Myr-CoA (**Fig. 1c**). Without Myr-CoA
9 pre-incubation, the binding constant of the reference peptide was significantly lower, indicating
10 the contribution of Myr-CoA to the binding potency (**Fig. S3a,b**). When the crystal structure
11 of the NPAP1 peptide complexed with HsNMT1 was determined in the presence of Myr-CoA,
12 we also observed transformation of the peptide into the acylated product (**Fig. 2d; Fig. S2b**).
13 The associated IC_{50} value was similar to that of the reference peptide (**Table S1**) and the
14 binding constant was in the nanomolar range, similarly to that of the reference peptide.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33
34 Upon incubation in the presence of high HsNMT1 concentrations, we observed
35 transformation of the NPAP1 octapeptide into the acylated product induced by HsNMT1 (**Fig.**
36
37
38
39 **S4**). We hypothesized that peptides such as NPAP1 or the reference peptides behave as prodrug
40 inhibitors through a single-turnover mechanism ³⁴: once acylated by HsNMT1 in the first
41 reaction round, the myristoylated peptide product cannot dissociate from the enzyme,
42 preventing multiple reaction cycles and hence tightly inhibiting HsNMT1 catalysis. The
43 measured dissociation constants therefore reflect those of the myristoylated product, not simply
44 of the peptide substrate. To examine the actual involvement of the reactive N-terminal group
45 in this process, we assessed the impact of its deletion in the context of the reference peptide
46 (peptide Ac2 in **Fig. 1; Fig. S3c**), which led to a two orders of magnitude decrease in affinity
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 as assessed using two independent approaches (IC_{50} and ITC, **Fig. 1b, c**). In addition, a single
2 Gly2Ala substitution (Ala2) of the reference peptide led to a two orders of magnitude increase
3
4 in K_{Dapp} (Ala2, **Fig. 1b; Fig. S3d**). These data were in keeping with important involvement of
5
6 N-terminal amino group reactivity in the binding or the inhibition process. Taken together, the
7
8 data suggest that the reference peptide and NPAP1 acted as prodrugs.
9

10
11 We next wondered whether other peptides derived from the human proteome (i) not
12
13 identified as substrates (like NPAP1) or featuring the lowest catalytic efficiencies, and (ii)
14
15 displaying similarities with the logo could also act as HsNMT1 inhibitors. After screening
16
17 ~1500 protein N-termini starting with Gly2 in the human proteome, we selected 40
18
19 octapeptides from human sequences displaying the closest similarity with the logo at positions
20
21 3-7 (i.e., the HsNMT1 binding pockets) and challenged their inhibitory properties. None
22
23 displayed an IC_{50} value below 10 μ M (**Table S1**). As the closest number of similarities of this
24
25 set at positions 3-7 was 3 out of 5, we concluded that at least 4 similarities - like in NPAP1 and
26
27 the reference peptide - were required to trigger significant inhibition and potent binding of a
28
29 given peptide to HsNMT1.
30
31
32
33
34
35

36 Inhibition of HsNMT1 by the reference peptide was confirmed using a variety of
37
38 substrates featuring distinct sequences and kinetic constants (GNCVFKGN, GLCTSKPN,
39
40 GNVISGGS, GVSFSCPF, GVCCSKGT, GCSVSKKK; **Fig. S5**). We could not fit our data to
41
42 classic inhibition models (**Fig. S5b-d**), as expected with such an irreversible inhibitor. We
43
44 focused instead on measuring IC_{50} values (**Fig. S5a**), selecting peptide GCSVSKKK (SOS3)
45
46 for further systematic analysis and comparison of the inhibition parameters. We derived the
47
48 binding constant (K_{Dapp}) from kinetic measurements with this peptide to obtain a finer
49
50 measurement of the binding potency of the most potent inhibitors (**Fig. 1b**).
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Structure-activity relationship analysis of the series defines the sequence space leading to tight inhibition

The tight affinity of the reference peptide to HsNMT1 therefore appears to arise from its intrinsic high affinity, which was further entropically increased by its reaction with myristate and subsequent product formation⁷. The dissociation time of the product from the catalyst may be increased by too-high affinity of the product. To probe this hypothesis, we performed a structure-function analysis of the reference sequence, anticipating that decreasing peptide affinity would help release the product and increase the probability of transforming the inhibitor reference peptide into a substrate. Indeed, the NMT catalysis rate constant is limited by the release of the acylated peptide and directly relies on peptide affinity⁷. As a result, the K_m associated with a substrate is usually a direct readout of the associated affinity and determination of the k_{cat} is a direct readout of the off-rate (usually referred as k_5 , see³⁵). In this regard, we could check that an already N-myristoylated reference peptide (Myr-GNCFSKPR) did not behave as an effective inhibitor of HsNMT1 ($K_{Dapp} > 10 \mu\text{M}$). This data is in line with a very low backward on-rate (k_{-5}) of the free reaction product (see also *Introduction*).

We first extended the sequence length of the reference peptide by C-terminal amidation and with one or two additional Ala residues (**Fig. 1a**). The longer peptides were still inhibitors and the K_D values reaching one nanomolar with two additional Ala residues (**Fig. 1c,d; Fig. S3e-h**). The crystal structure of the amidated peptide complexed to HsNMT1 revealed a hydrogen bonding interaction involving both the NH and the C-terminal amides of Arg9 of the reference peptide ligand and the protein backbone carbonyl group of residue Ile469 of HsNMT1 (**Fig. 2e; Fig. S2c**). Interestingly, a reference peptide featuring a five-residue C-terminal extension (V₁₀PTLK₁₄) did not improve the binding potency compared with the reference peptide (**Fig. 1b**). Indeed, the associated crystal structure of the complex with

1 HsNMT1 indicated that the additional amino acids in the peptide did not promote novel
2 interactions with the enzyme's outer surface beyond the Arg9 residue (**Fig. 2f; Fig. S2e**). We
3 concluded that most of the binding properties of the series were contained within residues 2-9.
4
5

6
7 We next studied the effects of progressive deletions of the reference peptide. When
8 shortened by more than one residue at the C-terminus, the reference peptide was no longer a
9 potent inhibitor and behaved as a substrate (dashed line in **Fig. 1a**). Previous data demonstrate
10 a crucial role for Ser6Lys7 in efficient NMT catalysis³⁰. Even so, the short tetrapeptide GNCF
11 was a highly efficient substrate (**Fig. 1a**), suggesting that Asn3 provides sufficient affinity to
12 allow efficient Gly-myristoylation and does not require any other specific residues beyond
13 Phe5. We concluded that there are two major sources of peptide affinity: (i) the N-terminal part
14 of the peptide featuring critical aa3 (aa2-5), optimal with Asn; and (ii) the C-terminal side chain
15 featuring Ser6Lys7 (aa6-9). Residue 5 appeared to be important, likely to orientate aa3 properly
16 into the corresponding binding pocket. The C-terminal part beyond residue 7 also played a role
17 but to a lesser extent, as exemplified by the interaction networks related to the crystal structure
18 of HsNMT1 in complex with the Pro8Ala variant of the reference peptide (**Fig. S2d**).
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 To probe the impact of each residue of the octapeptide on NMT catalysis and inhibition,
37 single changes were sequentially introduced at positions 3 to 9 of the reference peptide. Alanine
38 scanning revealed that changes to positions 2-7 of the reference peptide turned them all into
39 substrates, unlike positions 8-9 (**Fig. 1d**). These data fully complement the reference peptide
40 deletion analysis and confirm a central role for residues 2-7 (**Fig. 1a**).
41
42
43
44
45
46
47

48 To better assess the sequence space around the reference peptide as an inhibitor, a set
49 of >30 additional peptide variants with single substitutions other than Ala were designed and
50 challenged with HsNMT1 (**Fig. 1d; Fig. S3i-m**). Again, the majority of changes converted the
51 reference peptide inhibitor into an HsNMT1 substrate, while only a few mostly conservative
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 (i.e., chemically related) substitutions maintained the inhibitory behavior. The Gly2
2 substitution space was investigated with Ala2 and β -Ala2 changes, both of which added an
3 extra methyl/methylene group on either the side or main chain and converted the reference
4 peptide into a substrate, but with only very poor efficiency for Ala (**Fig. 1d**). The Ala2 variant
5 was a poor inhibitor with an inhibition constant in the micromolar range (**Fig. 1b,c**). To
6 promote inhibition only, both Asn3 and Ser6 appeared to be irreplaceable by any other amino
7 acid, while position 5 required either (i) a very hydrophobic residue such as Leu, Tyr, or Phe,
8 or (ii) a residue with an amide group such as Asn or Gln (**Fig. 1d**). Position 4 could only be
9 substituted by short polar residues including Cys and Ser to prevent the variants behaving as
10 substrates (**Fig. 1d**). The catalytic efficiencies associated with the non-inhibiting, substrate
11 variants were usually of the same order of magnitude as those of the best substrates and several
12 orders of magnitude higher than those associated with inhibition alone (**Fig. 1d**). As a result,
13 such variants with efficient catalytic properties were disregarded as they did not match the
14 specifications of inhibitors, which must remain stable over time. Substitutions leading to
15 substrate behavior were also associated with a significant increase in the inhibition constant.
16 Finally, we noticed that this analysis could be considered a readout of unfavorable residues
17 leading to Gly-myristoylation. Indeed, a substitution reverting the inhibitor into a substrate
18 indicated that it likely decreased the binding potency to such an extent that it made catalysis
19 easier by significantly increasing the turnover number. Because the limiting step is product
20 release, this indicated a relaxed binding potency of the peptide. Starting with a peptide with
21 very high affinity, any decrease in binding was expected to favor improved catalytic
22 performance, as assessed by catalytic efficiency. Therefore, the higher the k_{cat}/K_m resulting
23 from a substitution, the more unfavorable HsNMT1 binding to the residue. This was the case
24 for Lys3- or Leu6-containing derivatives, which are known to need an almost perfect match to
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 the reference peptide to promote Gly-myristoylation³⁰. This readout from a synthetic reference
2 peptide sequence mirrors the analysis of those sequences compiled from existing proteins
3 which are or are not HsNMT1 substrates (see³⁰).
4
5
6

7 The consensus motifs of NMTs (GC[CS][FLT]SKI[RFD] for the best substrates or
8 G[NCAQ][CASV][FLC]S[KRC] for the overall set) are biased by extra Cys residues that do
9 not influence NMT-driven Gly-myristoylation but rather S-palmitoylation, a modification
10 governed by palmitoyltransferases that relies on previous Gly-myristoylation³⁰. In our current
11 analysis, a consensus sequence GN[CS][FLYNQ]SK[RP][RA] emerged, which closely
12 mimicked that obtained from our previous kinetic analysis of peptides arising from natural
13 sequences³⁰. The analysis confirmed the unique roles played by Asn3 and the Ser6Lys7 motif
14 in high affinity interactions. Of note, position 4 appears to favor small hydrophilic residues,
15 while position 5 better supports bulky side chains.
16
17
18
19
20
21
22
23
24
25
26
27

28 Gly-myristoylation therefore appears to involve two sets of ligands, those containing
29 Asn3 and those with Ser6Lys7. Simultaneous inclusion of both features leads to deleterious,
30 distorted effects in terms of catalytic turnover, as demonstrated by the strong inhibitory
31 behavior of the reference peptide. We retained G₂NSFSKPR (Ser4) as the chassis sequence for
32 downstream analysis, thereby avoiding issues related to manipulation of Cys-containing
33 peptides like the reference peptide.
34
35
36
37
38
39
40
41
42
43
44
45

46 **Lys-myristoylation-inspired design of potent HsNMT1 inhibitors allows substitution of** 47 **the reactive amino group with non-natural residues** 48

49 The Gly2Asn3 head group therefore appeared to be very difficult to modify into a closely
50 related di-amino acid to obtain a compound as potent as the reference peptide. We recently
51 showed that NMT can react with the side-chain of a Lys residue, provided it is properly
52
53
54
55
56
57
58
59

1 positioned at the N-terminus and not preceded by a Gly, which is more reactive ⁵. Interestingly,
2 we noticed that the structure of the complex of HsNMT1 with the *ac*Lys peptide N-terminal
3 group (*ac*-KSFSKPR, *ac*K) was very similar to that of the reference peptide (**Fig. 3a,b**). While
4 the *ac*Lys-starting peptide was a substrate of Lys-myristoylation, we wondered whether we
5 could design Lys-myristoylation inhibitors based on both the reference peptide chassis and the
6 acetylated lysine group to remove the non-substitutable Gly2Asn3 group. In addition to
7 acetylation (*ac*), we have shown that several substitutions of Gly2 make it possible to favor
8 Lys3 myristoylation, including Gly2Ala and *ac*Gly (see Ref ⁵).
9

10 We first used synthetic lysine mimics to assess the effects of side-chain length. We
11 shortened the basic side chain of lysine to ornithine (Orn, reduced by one CH₂), di-amino
12 butyrate (Dab, reduced by two CH₂s), and di-amino propionate (Dap, short basic chain
13 CH₂NH₂) in combination with various Gly2 substitutions (*ac*, *ac*G, A). *ac*[Orn], *ac*[Dap],
14 A[Orn], and *ac*G[Dab] did not undergo myristoylation even at the highest HsNMT1
15 concentrations (**Table 1**), unlike their close homologs, *ac*K, AK, *ac*GK and *ac*G[Orn]. We
16 hypothesized that such non-reactive compounds might act as HsNMT1 inhibitors. While the
17 *ac*[Dap] derivative was a poor inhibitor with an inhibition constant of $11 \pm 1 \mu\text{M}$, the *ac*[Orn]
18 derivative showed an order of magnitude higher affinity (**Fig. 4a**), suggesting that the N-
19 terminal reactive amino group – if properly aligned with the α -carbon through 2-3 carbon bonds
20 like in Orn or Dab – might contribute to binding while not promoting catalysis. This
21 encouraged us to further design and study compounds with N-terminal Orn and Dab variations
22 based on the GK sequence.
23

24 We first assessed *ac*G[Dab], [Dab], and A[Orn], all of which acted as potent
25 competitive inhibitors with IC₅₀ values of the order of the HsNMT1 concentration used in the
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

1 assay. This indicated a tight binding constant in the low micromolar range (i.e., <0.4 μM ; **Fig.**
2 **4a**). Dab and Orn but not Lys clearly led to strong inhibition.
3

4
5 To modify the amino group orientation towards the catalytic base and to mimic the Gly-
6 myristoylation-producing mechanism, we built two D-Orn derivatives: the enantiomeric
7 stereoisomer of L-Orn (**Fig. 4b**; symmetric branching of R_1 and R_2 with respect to $\text{Ca}3$) either
8 with *ac* or *acG* to optimize the filling of pocket 3. Interestingly, the *ac*[D-Orn] N-terminal
9 group was a remarkably close mimic of the GlyAsn dipeptide, like in the reference peptide
10 (**Fig. 3a,c**; **Fig. S2a,f,g**), while our previous work revealed that Asn is favored in pocket 3^{1,30}.
11 Both D-Orn derivatives were potent inhibitors, especially the *ac* version ($K_D=50$ nM). A similar
12 result was observed with *ac*[D-Dab] and A[D-Orn] derivatives (**Fig. 4a**), and *acG*[D-Orn],
13 G[D-Orn], and [D-Orn] derivatives were also strong inhibitors but to a lesser extent than *ac*[D-
14 Orn]. When *ac*[D-Orn] was installed on the NCS1-derived chassis – i.e., a non-optimal Lys-
15 myristoylation chassis without a hydrophobic position at position 5 – significant, though weak,
16 myristoylation was observed (**Table 1**). This indicated that potent inhibition was only possible
17 with an optimal fit for Lys-myristoylation, including a hydrophobic residue filling pocket 5.
18
19

20
21 The partition ratio r is defined as the value of the intersection minus 1 of the residual
22 enzyme E activity in function $[I]/[E]$. The r ratio defines the average number of turnover events
23 required to form a catalytically inactive enzyme "E" in the presence of an inhibitor "I"³⁶. D-
24 Dab or D-Orn derivatives of the *ac* series both had partition ratios of 1.5 (**Fig. 4c**), indicative
25 of very high inactivation efficiency with an inhibition on-rate similar to that of the off-rate.
26 Moreover, the partition coefficient of the corresponding variant of the reference peptide series
27 (Ser4) was 3 instead of 1.5 for *ac*[D-Orn], indicative of an improved binding constant for the
28 Lys-myristoylation series compared with the previous one (**Fig. 4c**).
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Finally, we obtained the crystal structure of [Dab] and *ac*[D-Orn] in complex with HsNMT1 and retrieved the complex without conversion of the substrate into a product (**Fig. 4d-g; Fig. S2f,g; Fig. S6a,b**). The complex featured direct binding of the D-Orn and Dab amino groups to the carboxy terminal base. The reactive amino group of the Dab side chain bonded directly with the carboxy-terminal base of HsNMT1 (**Fig. 4f,g; Fig. S2f,g**). Such direct bonding of the reactive amino group of both inhibitors was unlike the efficient GK peptide, which requires water-mediated binding and acylation⁵. This salt bridging was identical to the binding of the *ac*K and AK Lys-myristoylation substrate derivatives (**Fig. 3c,d**). This direct salt bridge created in the context of the D-Orn or Dab side chains, which leads to optimal sizing, is expected to be stronger than the one made with Lys and at least 100-fold less prone to reaction. This likely explains the lower reactivity and behavior of the D-Orn series as potent inhibitors. Both compounds bound to Thr282 (**Fig. 4d-g**). The non-acetylated Dab compound featured a water network within pocket 3, indicative of less bonding than both acetyl derivatives, perhaps explaining its lower binding constant (**Fig. 4f**).

In conclusion, (i) the chain length bringing the reactive amino group, (ii) the chiral conformation of the substituents R₁ and R₂ of the C α group facing pocket 3 (C α 3; **Fig. 3**, and **Fig. 4b**), and (iii) the optimal occupation of pocket 3 with a moderately bulky N-terminal moiety mimicking Asn were mandatory for effective Lys-myristoylation-based design of HsNMT1 inhibitors.

pH-dependent Lys-myristoylation is indicative of a different inhibition mechanism to Gly-myristoylation

Crystal structures of Gly-myristoylation-inspired NMT inhibitor complexes always revealed conversion of the peptide into the product, indicative of prodrug inhibitors^{5,6,30}. The crystal

1 structures of the two potent inhibitors *ac*[D-Orn] and [Dab] did not reveal myristoyl group
2 reactivity with the peptide. In contrast, the 3D structure obtained with the Lys-myristoylation
3 substrate *ac*G-[Orn] after crystallization growth performed under identical conditions did show
4 acylation ⁵. We hypothesized that the potency of the second series was mostly related to the
5 strong salt bridge between the amino group of the lysine homolog side-chains and the carboxy-
6 terminal base of HsNMT1. The pKa of the Lys amino reactive group and the unnatural mimics
7 like Orn, Dab, or Dap is indeed expected to be high (>10.5) and, under physiological pH, only
8 a very small fraction is uncharged (0.01% at pH 7.5).
9

10 We investigated whether the uncharged form corresponded to the actual reactive
11 compound. We compared the effects of both the Gly-myristoylation and Lys-myristoylation
12 series at pH 7.5 and 9.0, i.e., the pH range compatible with assay conditions, by measuring the
13 catalytic efficiency of myristoylation by HsNMT1 (**Fig. 5a**; **Fig. S7a,b**). The Gly-
14 myristoylation series was fully independent of pH regardless of peptide sequence (ARF6, GK,
15 SOS3). This indicated that Gly-myristoylation could be achieved with the same efficiency by
16 either deprotonation of the alpha amino group of Gly or by bypassing deprotonation. As the
17 pKa of the alpha amino group of Gly is ~7.7 and the pH of the cell is ~7.2, the prominent
18 physiological form corresponds to the positively-charged form (see dashed line in **Fig. 5a**),
19 which requires NMT-catalyzed deprotonation before reaction. The enzyme-catalyzed
20 deprotonation step is probably therefore not rate-limiting, as expected from the kinetic model,
21 which shows very high catalytic rates (k_d) compared with the overall rate, which is limited by
22 dissociation ⁷ (**Fig. 6a**).
23

24 We next investigated the influence of pH on the Lys-myristoylation peptide substrates
25 using two acetylated peptides derivatives, also from the ARF and GK series (*ac*ARF6, *ac*GK).
26 The data were different to the Gly-myristoylation series (**Fig. 5b**; **Fig. S7c,d**). In addition to
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

1 low rates of Lys-myristoylation involving k_{cat} values two orders of magnitude lower than those
2 of Gly-myristoylation (0.001 vs 0.1 s⁻¹ **Table 1**), there was strong pH dependence and the
3 increase in catalytic efficiency closely mirrored increases in the non-protonated form (**Fig. 5b**).
4 The same pH dependence of Lys-myristoylation was confirmed with AK substrates derived
5 from ARF and the reference peptides (**Fig. S8a**). We concluded that the mechanism of Lys-
6 myristoylation by HsNMT1 exploited the non-protonated version of the peptide. The
7 deprotonated peptide was only very poorly abundant within this pH range, suggesting that only
8 a small fraction (<0.1%) of the substrate is available for catalysis. As a result, one can deduce
9 that the rate of acylation catalysis in the Lys-myristoylation reaction ($k_4 > k_{cat}/0.1\% = 10 \text{ s}^{-1}$) is
10 very similar to that of the Gly-myristoylation reaction (16 s⁻¹; **Fig. 6**).
11
12
13
14
15
16
17
18
19
20
21
22
23

24 These data strongly suggested that the mechanism of inhibition of the Lys-
25 myristoylation-inspired peptides involved the protonated version (**Fig. 6b**). Interestingly, this
26 form is expected to predominate at physiological pH (**Fig. 5b, Fig. S8b**). This balance favoring
27 the charged species suggests an inhibition mechanism where Lys-myristoylation-inspired
28 compounds exert their inhibitory effect primarily through stabilization of the salt bridge created
29 in the ternary complex (“salt bridge inhibition pathway” in **Fig. 6b**). This contrasts with the
30 Gly-myristoylation-inspired inhibitors, which exert their inhibition solely through conversion
31 of the peptide into a product that remains strongly bound to the enzyme due to their high affinity
32 (“product-driven inhibition” in **Fig. 6a**). Nevertheless, one cannot formally exclude that the
33 very small proportion of deprotonated peptides may lead to myristoylation, as is the case with
34 the substrate peptide of the similar Lys-myristoylation series already identified⁵. If so, the most
35 potent ligands, such as those of the D-Orn series, should behave as potent prodrug inhibitors,
36 similar to Gly-myristoylation inhibitors. The mechanism shown in **Fig. 6b** takes this putative
37 secondary effect into account, which can be considered an inhibitor “rescue step”, with the
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 involvement of an alternative inhibitory step (“product-driven inhibition”). Product formation
2 of this series is unlikely to involve the deprotonated form arising from the salt bridge, since
3
4 direct deprotonation of the salt bridge is most unlikely to occur, as it systematically involves a
5
6 water-mediated interaction with the catalytic base considering all known mechanisms reported
7
8 to date for the GNAT family of acyltransferases ³⁷. In the model (**Fig. 6b**), there would
9
10 therefore be two inhibited stages with two inhibitory forms, the major one corresponding to the
11
12 enzyme-substrate complex and the minor one to the enzyme:product complex. This dual
13
14 inhibition promotes a virtual balance favoring tight inhibition, as assessed by the remarkably
15
16 low partition ratio of the series (**Fig. 4c**). Since the enzyme-substrate complex can dissociate
17
18 with an off dissociation rate (k_{-1} step in **Fig. 6b**) an order of magnitude higher than that of the
19
20 enzyme product dissociation (k_5 step in **Fig. 6b**), it is not unlikely that this inhibition eventually
21
22 leads to progressive, extremely slow rebalancing of the equilibrium towards the
23
24 enzyme:product form, which could even eventually become dominant (**Fig. 6b**).
25
26
27
28
29
30
31
32
33

34 **Salt bridging with the catalytic base is a common mechanism of potent inhibition of** 35 **NMTs** 36

37
38 We superimposed the 3D structures of HsNMT1 bound to the lead peptides (i.e. both reference
39
40 and *ac*[D-Orn]) of our two series based on an optimal peptide binding motif to those
41
42 corresponding to each of three already described main leads (SC-58272 ³⁸, DDD85646 ²³, and
43
44 IMP-1088 ¹⁸) displaying high affinity for NMTs (**Fig. 7a**). PCLX-001, an effective NMT
45
46 inhibitor in cancer ^{21,39,40}, was not included in the comparison. Notably, it closely resembles
47
48 DDD85646, differing only in a substitution of the active-site distant pyrazole ring, and its 3D
49
50 structure in complex with the target is unavailable. The binding of our series perfectly matched
51
52 that of the other compounds, all of which similarly occupy the NMT peptide binding site (**Fig.**
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

7a). The crystal structure of SC-58272 with *Saccharomyces cerevisiae* NMT reveals a direct interaction and salt bridging of the protonated amino group $N\gamma$ with the carboxy terminus base of Leu455 (d_{N-O} 3.1 Å with each O, PDB Id 2NMT³⁸). Similarly, DDD85646 and IMP-1088 also salt bridge with the carboxylic base guaranteed by their respective dimethylamino and piperazine groups (d_{N-O} of 2.9 Å and 2.7 Å, respectively; **Fig. S9a,b**), such groups displaying pK values of the order of 9.8. Because our Lys-myristoylation series was identified through fully independent approaches, we conclude that tight inhibition to NMT without catalysis involves similar binding mechanisms.

Of our two series, the initial series based on Gly-myristoylation mimicry is unique as it does not take advantage of the salt bridge but rather the catalytic pathway (**Fig. 6a**). We noticed that each of these three small compounds inhibited several NMTs, including fungus and parasite NMTs. We therefore wondered if the reference series not involving a salt bridge could also inhibit NMTs other than HsNMT1. To test this, we focused on a selection of NMTs each recapitulating a type of NMT sequence and eukaryotic diversity (see phylogenetic analysis in Refs ^{1,2}). We first confirmed that HsNMT2 was also potently inhibited with similar inhibition binding constants (**Fig. 7b**). We next examined the plant *A. thaliana* NMT (AtNMT), and again observed potent inhibition. Finally, we challenged two further NMTs from unicellular eukaryotes, the apicomplexan *Plasmodium falciparum* (PfNMT) (which causes malaria) and the yeast *Saccharomyces cerevisiae* (ScNMT) ⁴¹. Remarkably, potent inhibition was observed in both cases (**Fig. 7b**). We concluded that optimal substrate mimicry was a relevant alternative to salt bridging inhibition to inhibit NMTs.

Discussion

The amino terminal salt bridge is a key structural element common to potent NMT inhibitors

The search for potent NMT inhibitors has taken advantage of peptidomimetics combining (i) mimicry with the best substrates known at the time (yeast Arf2p); (ii) N-terminal Gly to Ala substitution to prevent the reaction (yielding ALYASKLS-NH₂); (iii) redesign of the amino terminal tripeptide to an alkyl chain of varying length; and (iv) altering the N-terminal amino group into imidazole derivatives⁴²⁻⁴⁶. All the lead compounds, including the 2-methyl imidazole substitution of the semi-peptidic compound SC-58272, display in common (i) a chemical group ensuring a protonated N-terminus; (ii) Ser6 and Lys7 side chains or nonpeptidic mimics of both; and (iii) inhibition constants in the sub-micromolar range. Provided the distance between these crucial groups ensures the salt bridge, the best compounds originating from this approach behave as moderately potent and specific NMT inhibitors.

Screening strategies supported by medicinal chemistry approaches have identified new classes of NMT inhibitors⁴⁷, including potent, nanomolar inhibitors with effects against infections caused by *Trypanosoma brucei*, *Leishmania donovani*, and *P. falciparum*^{11,18,23,48-50}. These include the most effective NMT inhibitors reported to date, IMP-1088¹⁸ and DDD85646²³. Structural approaches indicate that all known compounds inhibit by direct competition only with the peptide-binding site (**Fig. 7a**). While belonging to distinct chemical families, IMP-1088 and DDD85646 display common interaction features (**Fig. S9a**): salt bridging with the carboxylic base guaranteed by their respective dimethylamino and piperazine groups, and deep entry into pocket 5 with hydrogen bonds (d_{N-O} 2.9 Å) between Ser405 and their common distal pyrazole groups⁵¹. Interestingly, though Ser405 is well conserved amongst NMTs, it is substituted with a Leu (L334) in fungi such as *S. cerevisiae*, which would be expected to clash with the pyrazole group and prevent the hydrogen bonding interaction in

1 fungal NMTs (**Fig. S9b**). Our compounds favor either a stacking interaction between the two
2 hydrophobic groups of each partner or a hydrogen bond induced by inhibitor residues featuring
3 an amide group, most likely with Ser405 of HsNMT1. Unlike the peptide mimics described in
4 this study featuring a hydrophobic residue at position 5, the small compounds of the IMP or
5 DDD series or those with an amide group at position 5 of our series are therefore not expected
6 to inhibit fungal NMTs.
7
8
9
10
11
12
13

14 Remarkably, the potency of both of our substrate-inspired series also depends on the
15 interaction between the C-terminal carboxyl group of Gln496 through the primary amino group
16 of either a lysine or the N-terminal group for Gly2. Interestingly, the Lys-myristoylation series
17 forms a salt bridge similar to the IMP and DDD series. Like the previous series, the
18 hydrophobic character of the group entering pocket 5 is also prominent, but there is no
19 interaction with Ser405, which is located within 3.6 Å of the phenyl ring (PDB Id 6QRM, do-
20 c). Instead, the distal interactions with pockets 6 and 7 – which do not occur with IMP-1088
21 and DDD85646 - are strong enough to trigger the potency as demonstrated, for instance, in the
22 deletion analysis. Either the Ser405 hydrogen bonding with the small compounds or the Lys6
23 salt bridging with the peptidomimetic series promote the closure of the ab-loop, which protects
24 the compounds from premature release (i.e., the interaction decreases the off rate). Of note, the
25 ab-loop closure stabilization includes another Lys107-Asp184 internal salt bridge (see
26 Supplementary Figure 14 in Ref. ⁶). Clearly, all series described to date exert their potency
27 through very similar mechanisms involving both the catalytic base and ab-loop closure as
28 triggered by a more distant interaction. Respect of the distance between the two elements is
29 also important, as evidenced either by the fragment-based design of IMP-1088 made through
30 ligation between IMP-772 and IMP-358 or by the random screening of a sub-library from the
31 original DDD64558 pyrazole hit to generate DDD85646 ^{18,23}. Taking everything into account,
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 these compounds bear a striking resemblance in terms of their spatial occupancy within the
2 active site peptide pocket. Our series and IMP-1088 both take advantage of pocket 3 either
3 filled with the N-terminal acetyl moiety or two hexyl groups, respectively (**Fig. S9c,d**). We
4 previously confirmed a large space in this pocket which may even be filled with two linear
5 amino acids or one as large as methionine ⁵. However, the inhibitory properties of our series
6 appear poorly compatible with larger chains better mimicking IMP-1088 in this pocket (**Fig.**
7 **1d**). This probably relates to the interaction with the catalytic base (Gln496) and how both the
8 length and the angle are altered by the overall restraints on the main backbone. Our series
9 brings additional constraints due to filling pockets 6 and 7, unlike IMP-1088. Finally, while
10 outside the peptide binding site, positions 8 and 9 also contribute to the binding, with several
11 side chains inducing destabilization of the resulting complex (**Fig. 1d**).
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

32 **Role of the protonability of the amino terminal group in overall NMT catalysis and** 33 **inhibition**

34 The alpha amino terminal group of proteins (N α) is a frequent site of protein reactivity and
35 associated modifications. It is also the most diverse site, with 82 distinct modifications
36 described to date ranging from -89 Da to +738 Da ^{52,53}. This high reactivity is not only due to
37 it being the first common reactive group to emerge from the ribosomal tunnel during protein
38 synthesis but also because N-termini are >80% solvent exposed ⁵⁴ and because the neutral pK
39 of the alpha amino group (7.7 ± 0.5 ⁵⁵) is close to the intracellular pH (7.2 ± 0.2). Easy enzyme-
40 mediated deprotonation makes the alpha amino group behave as a nucleophile and react with
41 a variety of donors – N-acetyl in the first place – to create various bonds. The protonability and
42 acidobasic character of the primary amine are lost upon amide bond creation by formylation,
43 acetylation, or fatty acylation.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Recent data have revealed a Gly-myristoylation mechanism for NMT and the importance of a water channel and water-mediated bond of the N-terminal alpha group of Gly to the C-terminal carboxyl group (Gln496), which acts as catalytic base promoting deprotonation and further catalytic reactivity ^{1,6}. Here we show that, with respect to Gly-myristoylation, NMT catalysis proceeds as efficiently with either protonated or deprotonated alpha amino group peptide substrates. This arises from the very efficient NMT deprotonation rate, which is not limiting with respect to the other steps of catalysis. NMT can also catalyze Lys-myristoylation on a series of N-substituted model targets, provided that a side-chain amino group is properly positioned on the polypeptide donor ⁵. Such a reactive group - usually belonging to a Lys residue (so-called ϵ) - needs to be located close to the N-terminus of the substrate to properly attain the active site base. In this study, we show that Lys-myristoylation makes deprotonation extremely difficult because of the salt bridge between the ammonium ion and the carboxylate base; in contrast, catalysis may proceed efficiently with the deprotonated ϵ -amino group. The deprotonated form of a Lys side chain is, however, extremely poorly abundant at physiological pH. This explains the low efficiency of the Lys-myristoylation reaction compared with Gly-myristoylation. This effect is therefore linked to the combined effect of the higher pK value of a side chain with respect to the α -amino group and the direct salt bridge. A major consequence is the higher affinity of the complex and further significant slowing of the catalytic rate. Primary amines appear to promote the strongest salt bridges over secondary or tertiary amines ⁵⁶. As the N-O distance needs to be less than 4 Å with an optimum in the 2.5-3.2 Å range and the angle made between the two bonds is best if around 0° ⁵⁶, strengthening and optimizing binding requires a perfect fit in the active site crevice. This is ensured here by the linker with the more remote interaction areas. Salt bridges contribute only rarely to protein-ligand atomic interactions, far less than hydrophobic, hydrogen, or π -staging

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

⁵⁷. Similar to NMT inhibitors, other systems have nevertheless demonstrated a major role for salt bridges in enzyme inhibition; due to their strength, they can induce a three orders of magnitude increase in potency, as in the case of protein kinase inhibitors ⁵⁸. This increase is comparable to the binding constant increase that the amino group of IMP-72 brings to IMP-358 when ligated to generate IMP-917, a compound closely related to IMP-1088 ¹⁸.

Conclusions

Here we show that peptide substrates displaying optimal fit and affinity with NMTs behave as inhibitors due to the persistent and slow dissociation time of the associated myristoylated product. Note that product release corresponds to the limiting step of NMT-catalyzed myristoylation ⁷. The combination of these two inhibitory effects – one taking advantage of salt bridge formation and the other the slow dissociation of the product - led to the design of potent Lys-myristoylation-inspired inhibitors. These molecules represent a departure from classic substrates and can be considered first-in-class. By contrast, Gly-myristoylation peptides of the same series closely mimic the actual NMT substrate and already behave as potent inhibitors with binding constants in the nanomolar range. By using them to probe other NMTs and challenge their respective peptide-binding pockets, we reveal that NMTs of various phyla share common inhibitory properties with this series. Finally, we show that NMT-catalyzed myristoylation likely evolved and converged independently from two types of ligands, including those containing Asn3 and those with Ser6Lys7. Combining both features reduces catalytic turnover, as demonstrated by the strong inhibitory behavior of the reference peptide. This might explain why the reference sequence is not the favorable, unique myristoylation signal in any organism. A remarkable behavior is that of the Lys3-containing substrates, which can only tolerate Ser6Lys7 to promote Gly-myristoylation ⁵. Taken together, the binding effects

1 of all positions are additive and together lead to potent inhibition. To ensure efficient protein
2 myristoylation, recognition patterns on the substrates therefore require a trade-off between
3
4 specific binding/targeting and an affinity that allows significant release of the product.
5
6

7 8 9 **Acknowledgments**

10 This work was supported by French National Research Agency (ANR) PalMyProt and
11
12 DynaMYT (references n° ANR-2010-BLAN-1611-01; ANR-20-CE44-0013) and Fondation
13
14 ARC (reference n° ARCPJA32020060002137) grants to TM. This work has benefited from a
15
16 French State grant (Saclay Plant Sciences, reference n° ANR-17-EURE-0007, EUR SPS-GSR)
17
18 under a France 2030 program (reference n° ANR-11-IDEX-0003), from the I2BC
19
20 crystallization platform supported by FRISBI ANR-10-INSB-0005, from the facilities and
21
22 expertise of the I2BC proteomic platform (Proteomic-Gif, SICaPS) supported by IBiSA, Ile de
23
24 France Region, Plan Cancer, CNRS and Paris-Saclay University, and from COST Action
25
26 CA20113, supported by COST (European Cooperation in Science and Technology). FR was
27
28 supported by the PhD fellowship ARDoc program from Region Ile-de-France (17012695) and
29
30 by Fondation pour la Recherche Médicale (FDT202001010779). We thank the French National
31
32 Synchrotron Facility (SOLEIL) for provision of synchrotron radiation facilities and the staff of
33
34 the PROXIMA-1/2 beamlines and the European Synchrotron Radiation Facility (ESRF) for
35
36 help with data collection. We strongly acknowledge Benoît Castrec, Sarah Ciccone, Michel
37
38 Desmadril, Magali Nicaise-Aumont, Jean-Pierre Le Caer, and Laila Sago for contributions in
39
40 the early stages of the project.
41
42
43
44
45
46
47
48
49
50
51

52 **Author contributions**

53
54
55
56
57
58
59
60
61
62
63
64
65

1 Conceptualization, T.M.; Methodology, F.R., C.D. and T.M.; Investigation, F.R., C.D., R.F.D.
2 and P.M.; Writing – Original Draft, C.G. and T.M.; Writing – Review & Editing, T.M.;
3
4 Funding Acquisition, C.G. and T.M.; Resources, F.R., C.D., R.F.D., P.M. and T.M.;
5
6 Supervision, T.M.
7
8
9

10 11 12 **Declaration of interests**

13
14
15 The authors declare no competing interests.
16
17
18
19
20

21 **Supplemental information**

22
23
24 Supplementary information is available for this paper.
25

26 Document S1. PDF file containing Figures S1-9 and Tables S1-3
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59

Figure legends

Figure 1. Structure-activity relationship and associated inhibitory potency of the reference peptide series.

Error bars correspond to standard deviations of three replicates. (a) Impact of peptide length using the reference peptide series. The associated k_{cat}/K_m was measured and values highlighted and linked with a dotted line. When the value was less than $0.01 \text{ M}^{-1}\cdot\text{s}^{-1}$ (i.e., the lowest detectable value), the IC_{50} was measured. The associated IC_{50} is indicated with plain bars with the scale indicated on the right ordinate scale. The scale is discontinuous starting from $10 \text{ }\mu\text{M}$ and indicates a highest value of $100 \text{ }\mu\text{M}$. Inhibition properties were classified from the strongest (green) to intermediate (beige) to the weakest (red). (b) Apparent dissociation constants of some variants of the reference peptide series as measured in their presence with the kinetic assay. Values were calculated as reported in STAR Methods. (c) Binding constants of the same series as measured by ITC. (d) Structure-activity relationship analysis of the reference peptide series (G_2NCFKPR) with unique substitutions indicated below were measured and reported. No bar indicates that the peptide is not a substrate within a value less than $0.01 \text{ M}^{-1}\cdot\text{s}^{-1}$.

Figure 2. Cartoons detailing peptide binding within the active site groove of HsNMT1.

Magnified view of the active site of HsNMT1 crystallized in the presence of the indicated peptide and Myr-CoA. The peptide is shown in yellow (panels a-d), turquoise (panel e), or magenta (panel f); the myristate in purple; and the HsNMT1 surface around the ligand in grey (surface) and green (ribbon). Slice depth in panels a-d was $8\text{-}12 \text{ \AA}$. The various pockets and

1 residues are displayed and hydrogen bonds are indicated as dashed lines. (a-c) GNCFSKPR
2 (reference peptide). (d) GNLLSKFR (NPAP1). (e) GNCFSKPR-NH₂ (C-amidated variant of
3 the reference peptide). The new hydrogen bonding around Arg9 is displayed. (f)
4 GNCFSKPRVPTLK (reference peptide fused to mouse Bax-inhibiting tetrapeptide ⁵⁹). A
5 close-up focusing on the C-terminal side of the peptide is displayed, and the residues are
6 labelled in turquoise.
7
8
9
10
11
12
13
14
15
16

17 **Figure 3. Binding modes of various peptides next to the catalytic base, the catalyst**
18 **platform, and the aa2 pocket.**
19

20
21
22 Pocket 3 - the pocket usually hosting amino acid 2 in Gly-myristoylation ¹ - filling by the
23 peptide moiety is schematized from the crystal structure data in the presence of various
24 inhibitors or substrates. Gln496 bears the carboxy-terminal catalytic base. Hydrogen bonding
25 is displayed as dashed lines. When water-mediated bonding occurs, the water molecule is
26 displayed in turquoise (Wat2; see nomenclature of water molecules in Ref. ¹). Pocket 3 is
27 displayed as a red cavity. Thr282 is the catalyst platform. Hydrogen bonding is displayed with
28 a red dotted line. Distances in angstroms (Å) are indicated in red or in turquoise if water-
29 mediated. Chirality of the peptide bonds is highlighted to show the high resemblance of Gly-
30 Asn with *ac*[D-Orn]. (a) GNCSFSKRRRA derivative of the reference peptide (PDB ID 6QRM).
31
32 (b) Ac-KSFSKPR variant (*ac*K, PDB ID 7OWO, ⁵). (c) *ac*[D-Orn] derivative of the reference
33 peptide (PDB ID 8Q23). (d) Ala2-Lys3 derivative of the reference peptide (PDB ID 7OWN,
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

60 **Figure 4. Characterization of Lys-myristoylation-inspired inhibitors of NMT.**
61
62
63
64
65

1 The peptides are derived from the GK peptide. Error bars correspond to standard deviations of
2 three replicates. (a) Apparent binding constants were derived from IC_{50} values according to ⁶⁰.
3
4 All reactants but the reactive peptide SOS3 were pre-incubated in the presence of the two
5
6 peptides for 30 minutes. The reaction was triggered by the addition of SOS3 and followed for
7
8 60 minutes. (b) Summary of the rules leading to NMT inhibition. (c) Plot showing that the
9
10 *ac*[D-Orn] (black circles) and *ac*[D-Dab] (grey squares) derivatives display low partition ratios.
11
12 The *ac*[L-Orn] inhibition pattern is indicated (black triangles). The reaction was triggered by
13
14 the addition of the productive substrate after pre-incubation of the inhibitor for 60 minutes in
15
16 the presence of Myr-CoA and HsNMT1. Time-course analysis was next performed to
17
18 determine the remaining enzyme activity. A value of 100 was given to the value obtained in
19
20 the absence of inhibitor due to the bi:bi mechanism, with Myr-CoA required to form the
21
22 complex ^{27,61}. (d) 3D and (e) planar representations of the interaction networks around the
23
24 *ac*[D-Orn] derivative bound to HsNMT1. (f) and (g) same as panels d and e, respectively, but
25
26 with Dab. Distances in angstroms (Å) are indicated in red and displayed as red dotted lines.
27
28
29
30
31
32
33
34
35
36

37 **Figure 5. Unlike Gly-myristoylation substrates, Lys-myristoylation substrates show tight**
38 **pH sensitivity.**

39
40
41 *k_{cat}/K_m* measurements of various HsNMT1 substrates (left bar ordinate) as a function of pH.
42
43 The averaged value trend are shown as colored lines (green, panel a; orange, panel b). The
44
45 percentage of the protonated form (right bar ordinate) is indicated with dashed black lines
46
47 taking the values of 7.7 and 10.5 as the pK values of the alpha and epsilon groups of Gly and
48
49 Lys residues, respectively. Complete pH range theoretical values are available in **Fig. S8b,c**.
50
51 Error bars correspond to standard deviations of three replicates. (a) Gly-myristoylation
52
53 substrates. *K_m* and *k_{cat}* profiles are provided in **Fig. S7** (b) Lys-myristoylation substrates. The
54
55
56
57
58
59
60
61
62
63
64
65

1 data associated with alanine-starting derivatives – also Lys-myristoylated - are provided in **Fig.**
2 **S8a**. The same trend was observed.
3

4
5
6
7 **Figure 6. Gly- and Lys-myristoylation display distinct inhibition mechanisms, both**
8 **eventually leading to the same inhibitory complex.**
9

10
11
12 (a) Inhibition model for the Gly-myristoylation-inspired series (G-Inhib). (b) Inhibition model
13 for the Lys-myristoylation-inspired series (K-Inhib). KH^+ -Inhib refers to the protonated amino
14 group of the Lys side chain (C ϵ position), or any Lys mimic including Orn or D-Orn (C δ
15 position), while K-Inhib corresponds to the deprotonated form.
16
17
18
19
20
21
22
23
24

25 **Figure 7. The reference inhibitor series displays close similarities to other potent**
26 **inhibitors and is a potent inhibitor of representative members of NMT diversity.**
27

28
29
30 (a) The 3D structures of HsNMT1 co-crystallized with the reference peptide (PDB Id 6QRM,
31 grey, bottom) and Ac[D-Orn] inhibitor (PDB Id 8Q23, this study, orange, top), ScNMT with
32 SC-58272 (PDB Id 2NMT, green), and HsNMT1 with DDD85646 (PDB Id 3IWE, turquoise)
33 were aligned with that of HsNMT1 with IMP-1088 (PDB Id 5MU6, magenta). The NMT
34 structures are not shown, and only the small inhibitor compounds are displayed as sticks with
35 carbon in the above colors for each compound. Both top and bottom panels are in the same
36 orientation, with the bottom panel slightly rotated around the y axis to better evidence the
37 unique N-terminal residue of Gly2. Top, overlay of Ac[D-Orn] with SC-5872, IMP-1088, and
38 DDD85646. Bottom, same as top but reference peptide used instead of Ac[D-Orn]. (b) IC_{50}
39 values were measured in the presence of 50 μM of SOS3 peptide with increasing concentrations
40 of the reference peptide in the presence of Myr-CoA and the indicated NMT. ScNMT was 0.1
41 μM ; PfNMT, HsNMT1, HsNMT2, and AtNMT were all 0.5 μM . The $\text{IC}_{50}/[\text{E}_0]$ ratio is
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59

calculated for each NMT. This ratio is a value that allows direct comparison of the respective binding constants. Error bars correspond to standard deviations of three replicates.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Tables

Table 1. Substitutions around the N-terminus of peptides promoting side chain MYR or NMT inhibition

Series	Peptide sequence	Short name (text & figures)	PDB ID	Kinetic parameters		
				k_{cat} (s ⁻¹)	K_m (μ M)	k_{cat}/K_m (s ⁻¹ .M ⁻¹)
acGK	ac-GKSFSKPR	acGK	6KS2	0.0017 ± 0.0002	58 ± 15	30 ± 6
	ac-G[Orn]SFSKPR	acG[Orn]	7OWP	0.0006 ± 0.0001	22 ± 3	29 ± 3
	ac-G[Dab]SFSKPR	acG[Dab]		NM	NM	<<0.01
	ac-G[D-Orn]SFSKPR	acG[D-Orn]		NM	NM	<<0.01
XK	AKSFSKPR	AK	7OWO	0.0006 ± 0.0002	14 ± 5	40 ± 11
	A[Orn]SFSKPR	A[Orn] ^c		NM	NM	<<0.01
	A[D-Orn]SFSKPR	A[D-Orn] ^c		NM	NM	<<0.01
	G[D-ORN]SFSKPR	G[D-Orn]		NM	NM	<<0.01
acK	ac-KSFSKPR	acK	7OWO	0.0009 ± 0.0001	24 ± 10	37 ± 13
	ac-[Orn]SFSKPR	ac[Orn]		NM	NM	<<0.01
	ac-[D-Orn]SFSKPR	ac[D-Orn]	8Q23	NM	NM	<<0.01
	ac-[D-Dab]SFSKPR	ac[D-Dab]		NM	NM	<<0.01
	ac-[Dap]SFSKPR	ac[Dap]		NM	NM	<<0.01
	ac-[D-Orn]SNSKLN					1.5
K	KSFSKPR	K		0.00043 ± 0.00004	16 ± 6	27 ± 6
	[Orn]SFSKPR	[Orn]		>0.0002		2
	[D-Orn]SFSKPR	[D-Orn]		NM	NM	<<0.01
	[Dab]SFSKPR	[Dab] ^c	8Q24	NM	NM	<<0.01

NM, not measurable; -, not measured or obtained.

STAR Methods

Resource availability

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Thierry Meinnel (thierry.meinnel@i2bc.paris-saclay.fr).

The crystal structures of NMT in complex with Myr-CoA and the peptides reported here have been deposited at the PDB under codes 8Q26, 8Q3T, 8Q3D, 8Q2Z, 8Q3S, 8Q23 and 8Q24.

Chemicals

All peptides (>95% purity) were purchased from Genscript Biotech Corporation (Rijswijk, Netherlands). NAD was purchased from Roche (Basel, Switzerland). All other chemicals were purchased from Sigma-Aldrich (St. Quentin, France). Stock solutions of myristoyl-CoA (0.2 mM) were prepared in sodium acetate, pH 5.6, and 1% Triton X-100, except for MALDI analysis, where cholate was used to reduce background.

As the N-terminal myristoylated residue is usually the second in the original ORF after the initial Met, we name this extreme N-terminal residue aa2 throughout this work.

NMT production

The long HsNMT1, HsNMT1[*I*], corresponding to residues 99-496 and devoid of the N-terminal unfolded domain, was cloned into a pET28 derivative vector featuring an N-terminal 10xHis tag fused with a Tobacco etch virus (TEV) protease cleavage site⁶². HsNMT1[*I*] was expressed at 22°C in BL21-PLysS Rosetta2 cells (Novagen, Sigma-Aldrich). Full-length HsNMT2, AtNMT, PfNMT, and ScNMT were purified as previously described^{30,41}. HsNMT1[*I*] was purified with the His-Tag removed after TEV cleavage as previously described^{6,62}. NMT overproducing cells are harvested by centrifugation and lysed by sonication after resuspension in 20 mM Tris-HCl (pH 8.0), 0.5 M NaCl, 5 mM 2-

1 mercaptoethanol, and 5 mM imidazole (buffer C) supplemented with 1 mg/mL lysozyme and
2 5 μ L benzonase. After centrifugation, the clarified lysate is loaded at 3 mL/min onto a nickel
3 affinity chromatography column (HisTrap Crude FF, 5 mL, GE Healthcare) and washed with
4 buffer C with 25 mM imidazole. Elution is carried out at 2 mL/min with buffer C plus 0.25 M
5 imidazole. The pool of purified HsNMT1 is next dialyzed overnight against 20 mM Tris-HCl
6 (pH 8.9), 150 mM NaCl, 25 mM imidazole, and 5 mM 2-mercaptoethanol in the presence of
7 TEV protease (1 mg per 15 mg purified protein). His-tag-free HsNMT1 is purified with a
8 HisTrap Crude FF column. The flow-through with HsNMT1 is diluted five times in 20 mM
9 Tris-HCl (pH 8.9) and 1 mM DTT (buffer B) and applied to an anion exchange chromatography
10 column (HiTrap Q FF, 5 mL, GE Healthcare). HsNMT1 is eluted with buffer B supplemented
11 with 0.2 M NaCl. Highly purified fractions are pooled, concentrated to 15–30 mg/ mL with an
12 Amicon centrifugal filtration device (Merck Millipore) in 20 mM Tris–HCl (pH 8.0), 0.2 M
13 NaCl, 1 mM DTT, and stored at -80°C before crystallization trials. Protein samples for kinetic
14 analysis are stored at -20°C in the same buffer plus 55% glycerol.

34 **Protein crystallization and structure determination**

35 *HsNMT1:Myr-CoA:inhibitor structures.* The HsNMT1[*I*] crystal structure in complex with
36 Myr-CoA was used to solve the structures of the complexes with ten different peptides in this
37 study. Suitable crystals of HsNMT1:Myr-CoA:inhibitor complexes were obtained by co-
38 crystallization using the hanging-drop vapor diffusion method at 20°C . Crystallization droplets
39 were formed by mixing 2 μ L of the HsNMT1:Myr-CoA:peptide complex (molar ratio
40 1:1.5:1.5) at 6-9 mg/mL with 2 μ L of the precipitant solution containing 0.1 M MgCl_2 , 0.2 M
41 NaCl, 0.1 M sodium citrate pH 5.6, and 18-24% (w/v) PEG 6K or 8K. Crystals were
42 cryoprotected in the reservoir solution supplemented with 15% (v/v) glycerol and flash cooled
43 in liquid nitrogen. Complete X-ray datasets of HsNMT1:Myr-CoA:inhibitors were collected at
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

100K the French National Synchrotron Facility (SOLEIL) PROXIMA-1 or PROXIMA-2 beamlines or at the European Radiation Synchrotron Facility (ESRF) with the BM14, ID30A1/MASSIF1, and ID30A3/MASSIF3 beamlines.

Datasets were integrated with XDS ⁶³ and scaled and reduced using AIMLESS from the CCP4 package ⁶⁴. Crystals belonged to the space group P2₁2₁2 with similar unit cell parameters (summarized in **Table S2**) and contained two NMT molecules per asymmetric unit. The structures of the HsNMT1:Myr-CoA:inhibitor complexes were solved using MOLREP ⁶⁵. C_α protein coordinates of the HsNMT1[*I*] model (PDB entry 5O9V) were used as the search model. Structures were subjected to alternating refinement cycles using REFMAC-5 and PHENIX and manual model building using COOT ⁶⁶⁻⁶⁸. The good quality electron density maps also enabled refinement of substrate peptide, reaction intermediate, and reaction product molecules bound to HsNMT1 in each complex. Chemical compound libraries were generated using PRODRG server ⁶⁹ in combination with eLBOW from the PHENIX suite. Difference electron density maps were calculated in PHENIX. Final model geometry was validated using MolProbity ⁷⁰. X-ray data collection and refinement statistics are summarized in **Table S2**. Figures were generated using PyMOL (DeLano Scientific LLC, <http://pymol.sourceforge.net/>). Omit electron density maps were calculated using PolderMap ⁷¹ from the PHENIX suite after omitting the peptide of each active site and excluding the bulk solvent around the omitted region. Ligand-protein interaction diagrams were generated with LigPlot+ v2.2.8 ⁷² and displayed in **Fig. S3**. A summary of the main features and figures related to the crystal structures associated to this work is provided in **Table S3**.

Measurements of activity and inhibition parameters

HsNMT1 activity was assayed at 30°C in a coupled assay using an updated, step-by-step, detailed version of the previously described protocol ^{73,74}. In brief, the reaction mixture

1 contained 50 mM Tris-HCl (pH 8.0), 1 mM MgCl₂, 0.193 mM EGTA, 0.32 mM DTT, 0.2 mM
2 thiamine pyrophosphate, 2 mM pyruvate, 0.1 mg/mL of BSA, 0.1% Triton X-100, 2.5 mM
3 NAD⁺, 0.125 units/mL of porcine heart PDH (0.33 units/mg), 40 μM Myr-CoA, and 1-2000
4 μM peptides. Unless otherwise stated for tight binding studies, the reaction mixture was pre-
5 incubated for 3 min at 30°C before starting the reaction by adding Myr-CoA. The final volume
6 was 200 μL, and kinetics were followed by either fluorescence- or absorption-based
7 spectrometry⁷⁴. An Infinite M Nano⁺ plate reader equipped with micro-injectors (Tecan, Lyon,
8 France) was set at 340 nm to monitor the absorbance over time at 30°C. Briefly, a reaction
9 mixture containing HsNMT1[I] at different concentrations of peptide acceptors was pre-
10 incubated for 3 min at 30°C before starting the reaction with Myr-CoA. Myristoylation kinetics
11 were monitored continuously for 30 min, and the data were fitted to obtain the initial velocities
12 associated with each peptide concentration. Curve fits to obtain kinetic parameters were
13 achieved by non-linear regression with GraphPad Prism 9.5 (GraphPad Software, La Jolla,
14 CA). Parameters with standard errors were computed for all parameters using the complete
15 dataset including replicates. Both k_{cat} and K_m kinetic parameters and associated standard
16 deviations were obtained by fitting to the Michaelis–Menten equation⁷⁴. k_{cat}/K_m values were
17 derived from both parameters and the associated standard errors were calculated as described
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

For inhibition assays, we used the same reaction mixture for up to 30 min at 30°C incubation in the presence of the inhibitor peptide and Myr-CoA. The reaction was triggered by the addition of G₂CSVSVKKK (SOS3) peptide and monitored for 30 min. Inhibition curves and associated IC₅₀ values were fitted using the GraphPad absolute IC₅₀ module with baseline set at 0. Inhibition constants were calculated as described in^{36,60,75} with $K_I = (IC_{50}-$

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

$[E]/2)/(1+[S]/K_m)$. The HsNMT1 concentration was 0.25 μM , and the substrate ($\text{G}_2\text{CSVSKKK}$; $K_m=18\pm 3 \mu\text{M}^{41,73}$) was used at a concentration of 20 μM .

Microcalorimetry

Purified HsNMT1 was dissolved in 20 mM H_3PO_4 pH 7.4, 0.3 M NaCl buffer. The binding parameters of HsNMT1 inhibitors were monitored at 30°C by isothermal titration calorimetry (ITC) on an ITC200 microcalorimeter (MicroCal, Malvern Panalytical, Malvern, UK). Peptides were dissolved in the same buffer. A total of 20-25 injections of 1.5-2 μL peptide (250-350 μM) were made from a computer-controlled 40 μL microsyringe at 180-240 s intervals into the solution (30 μM HsNMT1 mixed or not with 30 μM Myr-CoA, volume cell = 0.2 mL), with stirring at 310 rpm. Experimental data were fit to a theoretical titration curve using Origin software with ΔH (the enthalpy change), K_a (the association binding constant in M^{-1}), and n (the number of binding sites per monomer) as adjustable parameters and the total protein concentration and the free and total ligand concentrations as known parameters. Examples of analysis for each reported measurement are given in **Fig. S3a-m**.

Mass spectrometry

For MALDI-ToF/ToF analysis, 300 μL of a mixture containing 50 mM Tris (pH 8), 0.193 mM EGTA, 1 mM MgCl_2 , 1 mM DTT, 5 μM sodium cholate, 0.04 mM Myr-CoA solution (stock solution 0.2 mM Myr-CoA, 10 mM sodium acetate, 2.5 μM sodium cholate), 0.5 μM NMT, and 100 μM of synthetic peptide were incubated at 30°C. The myristoylation reaction was followed over time by collecting 10 μL samples further diluted in 90 μL of water/acetonitrile solution. The different samples were then diluted five times in the matrix solution made of 5 mg/mL of α -cyano-4-hydroxycinnamic acid solubilized in water/formic acid/acetonitrile (50/50/0.1%). 1 μL of each dilution was spotted on a metal target and dried. MS and MS/MS

1 spectra of each sample were acquired and analyzed with an AB SCIEX 5800 instrument in
2 positive ion mode as reported in ⁵.
3
4

5 **References**

- 6
7
8 1. Meinel, T., Dian, C., and Giglione, C. (2020). Myristoylation, an ancient protein
9 modification mirroring eukaryogenesis and evolution. *Trends Biochem Sci* *45*, 619-
10 632. 10.1016/j.tibs.2020.03.007.
11
12 2. Giglione, C., and Meinel, T. (2022). Mapping the myristoylome through a complete
13 understanding of protein myristoylation biochemistry. *Prog Lipid Res* *85*, 101139.
14 10.1016/j.plipres.2021.101139.
15
16 3. Kosciuk, T., and Lin, H. (2020). N-Myristoyltransferase as a glycine and lysine
17 myristoyltransferase in cancer, immunity, and infections. *ACS Chem Biol* *15*, 1747-
18 1758. 10.1021/acscchembio.0c00314.
19
20 4. Kosciuk, T., Price, I.R., Zhang, X., Zhu, C., Johnson, K.N., Zhang, S., Halaby, S.L.,
21 Komaniecki, G.P., Yang, M., DeHart, C.J., et al. (2020). NMT1 and NMT2 are lysine
22 myristoyltransferases regulating the ARF6 GTPase cycle. *Nat Commun* *11*, 1067.
23 10.1038/s41467-020-14893-x.
24
25 5. Rivière, F., Dian, C., Dutheil, R.F., Monassa, P., Giglione, C., and Meinel, T. (2022).
26 Structural and large-scale analysis unveil the intertwined paths promoting NMT-
27 catalyzed lysine and glycine myristoylation. *J Mol Biol* *434*, 167843.
28 10.1016/j.jmb.2022.167843.
29
30 6. Dian, C., Pérez-Dorado, I., Rivière, F., Asensio, T., Legrand, P., Ritzefeld, M., Shen,
31 M., Cota, E., Meinel, T., Tate, E.W., and Giglione, C. (2020). High-resolution
32 snapshots of human N-myristoyltransferase in action illuminate a mechanism
33 promoting N-terminal Lys and Gly myristoylation. *Nat Commun* *11*, 1132.
34 10.1038/s41467-020-14847-3.
35
36 7. Meinel, T. (2022). Comment on “Binding affinity determines substrate specificity and
37 enables discovery of substrates for N-Myristoyltransferases”. *ACS Catal* *12*, 8195-
38 8201. 10.1021/acscatal.2c01060.
39
40 8. Bhatnagar, R.S., Jackson-Machelski, E., McWherter, C.A., and Gordon, J.I. (1994).
41 Isothermal titration calorimetric studies of *Saccharomyces cerevisiae* myristoyl-
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- CoA:protein N-myristoyltransferase. Determinants of binding energy and catalytic discrimination among acyl-CoA and peptide ligands. *J Biol Chem* 269, 11045-11053.
9. Rudnick, D.A., McWherter, C.A., Rocque, W.J., Lennon, P.J., Getman, D.P., and Gordon, J.I. (1991). Kinetic and structural evidence for a sequential ordered Bi Bi mechanism of catalysis by *Saccharomyces cerevisiae* myristoyl-CoA:protein N-myristoyltransferase. *J Biol Chem* 266, 9732-9739. 10.1016/S0021-9258(18)92882-6.
10. Towler, D.A., Adams, S.P., Eubanks, S.R., Towery, D.S., Jackson-Machelski, E., Glaser, L., and Gordon, J.I. (1987). Purification and characterization of yeast myristoyl CoA:protein N-myristoyltransferase. *Proc Natl Acad Sci U S A* 84, 2708-2712. 10.1073/pnas.84.9.2708.
11. Wright, M.H., Clough, B., Rackham, M.D., Rangachari, K., Brannigan, J.A., Grainger, M., Moss, D.K., Bottrill, A.R., Heal, W.P., Broncel, M., et al. (2014). Validation of N-myristoyltransferase as an antimalarial drug target using an integrated chemical biology approach. *Nat Chem* 6, 112-121. 10.1038/nchem.1830.
12. Thinon, E., Serwa, R.A., Broncel, M., Brannigan, J.A., Brassat, U., Wright, M.H., Heal, W.P., Wilkinson, A.J., Mann, D.J., and Tate, E.W. (2014). Global profiling of co- and post-translationally N-myristoylated proteomes in human cells. *Nat Commun* 5, 4919. 10.1038/ncomms5919.
13. Broncel, M., Serwa, R.A., Ciepla, P., Krause, E., Dallman, M.J., Magee, A.I., and Tate, E.W. (2015). Multifunctional reagents for quantitative proteome-wide analysis of protein modification in human cells and dynamic profiling of protein lipidation during vertebrate development. *Angew Chem Int Ed Engl* 54, 5948-5951. 10.1002/anie.201500342.
14. Wright, M.H., Paape, D., Price, H.P., Smith, D.F., and Tate, E.W. (2016). Global profiling and inhibition of protein lipidation in vector and host stages of the sleeping sickness parasite *Trypanosoma brucei*. *ACS Infect Dis* 2, 427-441. 10.1021/acsinfecdis.6b00034.
15. Broncel, M., Dominicus, C., Vigetti, L., Nofal, S.D., Bartlett, E.J., Touquet, B., Hunt, A., Wallbank, B.A., Federico, S., Matthews, S., et al. (2020). Profiling of myristoylation in *Toxoplasma gondii* reveals an N-myristoylated protein important for host cell penetration. *eLife* 9, e57861. 10.7554/eLife.57861.

16. Majeran, W., Le Caer, J.P., Ponnala, L., Meinnel, T., and Giglione, C. (2018). Targeted profiling of *A. thaliana* sub-proteomes illuminates new co- and post-translationally N-terminal myristoylated proteins. *Plant Cell* *30*, 543-562. 10.1105/tpc.17.00523.
17. Maurer-Stroh, S., and Eisenhaber, F. (2004). Myristoylation of viral and bacterial proteins. *Trends Microbiol* *12*, 178-185. 10.1016/j.tim.2004.02.006.
18. Mousnier, A., Bell, A.S., Swieboda, D.P., Morales-Sanfrutos, J., Perez-Dorado, I., Brannigan, J.A., Newman, J., Ritzefeld, M., Hutton, J.A., Guedan, A., et al. (2018). Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus. *Nat Chem* *10*, 599-606. 10.1038/s41557-018-0039-2.
19. Priyamvada, L., Kallemeijn, W.W., Faronato, M., Wilkins, K., Goldsmith, C.S., Cotter, C.A., Ojeda, S., Solari, R., Moss, B., Tate, E.W., and Satheshkumar, P.S. (2022). Inhibition of vaccinia virus L1 N-myristoylation by the host N-myristoyltransferase inhibitor IMP-1088 generates non-infectious virions defective in cell entry. *PLoS Pathog* *18*, e1010662. 10.1371/journal.ppat.1010662.
20. Saber, S.H., Ojha, R., Quirin, T., Strandin, T., Kant, R., Kareinen, L., Yak, N., Sironen, T., Vapalahti, O., Balistreri, G., and Joensuu, M. (2023). The infectivity of SARS-CoV-2 progeny virions requires the activity of host cell N-myristoyltransferases and it is severely compromised by their inhibition. *bioRxiv*, 2023.2003.2003.530798. 10.1101/2023.03.03.530798.
21. Beauchamp, E., Yap, M.C., Iyer, A., Perinpanayagam, M.A., Gamma, J.M., Vincent, K.M., Lakshmanan, M., Raju, A., Tergaonkar, V., Tan, S.Y., et al. (2020). Targeting N-myristoylation for therapy of B-cell lymphomas. *Nat Commun* *11*, 5348. 10.1038/s41467-020-18998-1.
22. Tate, E.W., Soday, L., de la Lastra, A.L., Wang, M., and Lin, H. (2024). Protein lipidation in cancer: mechanisms, dysregulation and emerging drug targets. *Nat Rev Cancer*. 10.1038/s41568-024-00666-x.
23. Frearson, J.A., Brand, S., McElroy, S.P., Cleghorn, L.A., Smid, O., Stojanovski, L., Price, H.P., Guther, M.L., Torrie, L.S., Robinson, D.A., et al. (2010). N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. *Nature* *464*, 728-732. 10.1038/nature08893.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
24. Schlott, A.C., Knuepfer, E., Green, J.L., Hobson, P., Borg, A.J., Morales-Sanfrutos, J., Perrin, A.J., Maclachlan, C., Collinson, L.M., Snijders, A.P., et al. (2021). Inhibition of protein N-myristoylation blocks *Plasmodium falciparum* intraerythrocytic development, egress and invasion. *PLoS Biol* *19*, e3001408. [10.1371/journal.pbio.3001408](https://doi.org/10.1371/journal.pbio.3001408).
 25. Schlott, A.C., Mayclin, S., Reers, A.R., Coburn-Flynn, O., Bell, A.S., Green, J., Knuepfer, E., Charter, D., Bonnert, R., Campo, B., et al. (2019). Structure-guided identification of resistance breaking antimalarial N-myristoyltransferase inhibitors. *Cell Chem Biol* *26*, 991-1000.e1007. [10.1016/j.chembiol.2019.03.015](https://doi.org/10.1016/j.chembiol.2019.03.015).
 26. Rodríguez-Hernández, D., Vijayan, K., Zigweid, R., Fenwick, M.K., Sankaran, B., Roobsoong, W., Sattabongkot, J., Glennon, E.K.K., Myler, P.J., Sunnerhagen, P., et al. (2023). Identification of potent and selective N-myristoyltransferase inhibitors of *Plasmodium vivax* liver stage hypnozoites and schizonts. *Nat Commun* *14*, 5408. [10.1038/s41467-023-41119-7](https://doi.org/10.1038/s41467-023-41119-7).
 27. Bhatnagar, R.S., Ashrafi, K., Futterer, K., Waksman, G., and Gordon, J.I. (2001). Biology and enzymology of protein N-myristoylation. In *The Enzymes*, F. Tamanoi, and D.S. Sigman, eds. (Academic Press), pp. 241-286. [10.1016/S1874-6047\(01\)80022-6](https://doi.org/10.1016/S1874-6047(01)80022-6).
 28. Fang, W., Robinson, D.A., Raimi, O.G., Blair, D.E., Harrison, J.R., Lockhart, D.E., Torrie, L.S., Ruda, G.F., Wyatt, P.G., Gilbert, I.H., and van Aalten, D.M. (2015). N-myristoyltransferase is a cell wall target in *Aspergillus fumigatus*. *ACS Chem Biol* *10*, 1425-1434. [10.1021/cb5008647](https://doi.org/10.1021/cb5008647).
 29. Fenwick, M.K., Reers, A.R., Liu, Y., Zigweid, R., Sankaran, B., Shin, J., Hulverson, M.A., Hammerson, B., Fernández Álvaro, E., Myler, P.J., et al. (2023). Identification of and structural insights into hit compounds targeting N-myristoyltransferase for *Cryptosporidium* drug development. *ACS Infect Dis*. [10.1021/acsinfecdis.3c00151](https://doi.org/10.1021/acsinfecdis.3c00151).
 30. Castrec, B., Dian, C., Ciccone, S., Ebert, C.L., Bienvenut, W.V., Le Caer, J.-P., Steyaert, J.-M., Giglione, C., and Meinnel, T. (2018). Structural and genomic decoding of human and plant myristoylomes reveals a definitive recognition pattern. *Nat Chem Biol* *14*, 671-679. [10.1038/s41589-018-0077-5](https://doi.org/10.1038/s41589-018-0077-5).
 31. Takamitsu, E., Otsuka, M., Haebara, T., Yano, M., Matsuzaki, K., Kobuchi, H., Moriya, K., and Utsumi, T. (2015). Identification of human N-myristoylated proteins from

- human complementary DNA resources by cell-free and cellular metabolic labeling analyses. *PLoS One* 10, e0136360. 10.1371/journal.pone.0136360.
32. Traverso, J.A., Micalella, C., Martinez, A., Brown, S.C., Satiat-Jeunemaitre, B., Meinnel, T., and Giglione, C. (2013). Roles of N-Terminal fatty acid acylations in membrane compartment partitioning: Arabidopsis h-type thioredoxins as a case study. *Plant Cell* 25, 1056-1077. 10.1105/tpc.112.106849.
33. Neumann, L.C., Feiner, N., Meyer, A., Buiting, K., and Horsthemke, B. (2014). The imprinted NPAP1 gene in the Prader-Willi syndrome region belongs to a POM121-related family of retrogenes. *Genome Biol Evol* 6, 344-351. 10.1093/gbe/evu019.
34. Hougland, J.L., Hicks, K.A., Hartman, H.L., Kelly, R.A., Watt, T.J., and Fierke, C.A. (2010). Identification of novel peptide substrates for protein farnesyltransferase reveals two substrate classes with distinct sequence selectivities. *J Mol Biol* 395, 176-190. 10.1016/j.jmb.2009.10.038.
35. Farazi, T.A., Manchester, J.K., and Gordon, J.I. (2000). Transient-state kinetic analysis of *Saccharomyces cerevisiae* myristoylCoA:protein N-myristoyltransferase reveals that a step after chemical transformation is rate limiting. *Biochemistry* 39, 15807-15816. 10.1021/bi002074t.
36. Copeland, R.A. (2005). Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists (John Wiley & Sons).
37. Salah Ud-Din, A.I., Tikhomirova, A., and Roujeinikova, A. (2016). Structure and functional diversity of GCN5-related N-acetyltransferases (GNAT). *Int J Mol Sci* 17, E1018. 10.3390/ijms17071018.
38. Bhatnagar, R.S., Futterer, K., Farazi, T.A., Korolev, S., Murray, C.L., Jackson-Machelski, E., Gokel, G.W., Gordon, J.I., and Waksman, G. (1998). Structure of N-myristoyltransferase with bound myristoylCoA and peptide substrate analogs. *Nat Struct Biol* 5, 1091-1097. 10.1038/4202.
39. Sangha, R., Davies, N.M., Namdar, A., Chu, M., Spratlin, J., Beauchamp, E., Berthiaume, L.G., and Mackey, J.R. (2022). Novel, first-in-human, oral PCLX-001 treatment in a patient with relapsed diffuse large B-cell lymphoma. *Curr Oncol* 29, 1939-1946.
40. Mackey, J.R., Lai, J., Chauhan, U., Beauchamp, E., Dong, W.F., Glubrecht, D., Sim, Y.W., Ghosh, S., Bigras, G., Lai, R., and Berthiaume, L.G. (2021). N-

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- myristoyltransferase proteins in breast cancer: prognostic relevance and validation as a new drug target. *Breast Cancer Res Treat* 186, 79-87. 10.1007/s10549-020-06037-y.
41. Traverso, J.A., Giglione, C., and Meinnel, T. (2013). High-throughput profiling of N-myristoylation substrate specificity across species including pathogens. *Proteomics* 13, 25-36. 10.1002/pmic.201200375.
42. Nagarajan, S.R., Devadas, B., Zupec, M.E., Freeman, S.K., Brown, D.L., Lu, H.F., Mehta, P.P., Kishore, N.S., McWherter, C.A., Getman, D.P., et al. (1997). Conformationally constrained [p-(omega-aminoalkyl)phenacetyl]-L-seryl-L-lysyl dipeptide amides as potent peptidomimetic inhibitors of *Candida albicans* and human myristoyl-CoA:protein N-myristoyl transferase. *J Med Chem* 40, 1422-1438. 10.1021/jm9608671.
43. McWherter, C.A., Rocque, W.J., Zupec, M.E., Freeman, S.K., Brown, D.L., Devadas, B., Getman, D.P., Sikorski, J.A., and Gordon, J.I. (1997). Scanning alanine mutagenesis and de-peptidization of a *Candida albicans* myristoyl-CoA:protein N-myristoyltransferase octapeptide substrate reveals three elements critical for molecular recognition. *J Biol Chem* 272, 11874-11880. 10.1074/jbc.272.18.11874.
44. Devadas, B., Freeman, S.K., Zupec, M.E., Lu, H.F., Nagarajan, S.R., Kishore, N.S., Lodge, J.K., Kuneman, D.W., McWherter, C.A., Vinjamoori, D.V., et al. (1997). Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of *Candida albicans* myristoylCoA:protein N-myristoyltransferase and identification of related tripeptide inhibitors with mechanism-based antifungal activity. *J Med Chem* 40, 2609-2625.
45. Devadas, B., Freeman, S.K., McWherter, C.A., Kishore, N.S., Lodge, J.K., Jackson-Machelski, E., Gordon, J.I., and Sikorski, J.A. (1998). Novel biologically active nonpeptidic inhibitors of myristoylCoA:protein N-myristoyltransferase. *J Med Chem* 41, 996-1000. 10.1021/jm980001q.
46. Olaleye, T.O., Brannigan, J.A., Roberts, S.M., Leatherbarrow, R.J., Wilkinson, A.J., and Tate, E.W. (2014). Peptidomimetic inhibitors of N-myristoyltransferase from human malaria and leishmaniasis parasites. *Org Biomol Chem* 12, 8132-8137. 10.1039/c4ob01669f.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
47. Zhao, C., and Ma, S. (2014). Recent Advances in The Discovery of N-Myristoyltransferase Inhibitors. *ChemMedChem* 9, 2425-2437. 10.1002/cmdc.201402174.
 48. Bell, A.S., Mills, J.E., Williams, G.P., Brannigan, J.A., Wilkinson, A.J., Parkinson, T., Leatherbarrow, R.J., Tate, E.W., Holder, A.A., and Smith, D.F. (2012). Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs. *PLoS Negl Trop Dis* 6, e1625. 10.1371/journal.pntd.0001625.
 49. Paape, D., Bell, A.S., Heal, W.P., Hutton, J.A., Leatherbarrow, R.J., Tate, E.W., and Smith, D.F. (2014). Using a non-image-based medium-throughput assay for screening compounds targeting N-myristoylation in intracellular *Leishmania amastigotes*. *PLoS Negl Trop Dis* 8, e3363. 10.1371/journal.pntd.0003363.
 50. Goncalves, V., Brannigan, J.A., Whalley, D., Ansell, K.H., Saxty, B., Holder, A.A., Wilkinson, A.J., Tate, E.W., and Leatherbarrow, R.J. (2012). Discovery of *Plasmodium vivax* N-myristoyltransferase inhibitors: screening, synthesis, and structural characterization of their binding mode. *J Med Chem* 55, 3578-3582. 10.1021/jm300040p.
 51. Spassov, D.S., Atanasova, M., and Doytchinova, I. (2023). A role of salt bridges in mediating drug potency: A lesson from the N-myristoyltransferase inhibitors. *Front Mol Biosci* 9, 1066029. 10.3389/fmolb.2022.1066029.
 52. Devabhaktuni, A., Lin, S., Zhang, L., Swaminathan, K., Gonzalez, C.G., Olsson, N., Pearlman, S.M., Rawson, K., and Elias, J.E. (2019). TagGraph reveals vast protein modification landscapes from large tandem mass spectrometry datasets. *Nat Biotechnol* 37, 469-479. 10.1038/s41587-019-0067-5.
 53. Meinel, T., and Giglione, C. (2022). N-terminal modifications, the associated processing machinery, and their evolution in plastid-containing organisms. *J Exp Bot* 73, 6013-6033. 10.1093/jxb/erac290.
 54. Rosen, C.B., and Francis, M.B. (2017). Targeting the N terminus for site-selective protein modification. *Nat Chem Biol* 13, 697-705. 10.1038/nchembio.2416.
 55. Pace, C.N., Grimsley, G.R., and Scholtz, J.M. (2009). Protein ionizable groups: pK values and their contribution to protein stability and solubility. *J Biol Chem* 284, 13285-13289. 10.1074/jbc.R800080200.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
56. Kurczab, R., Śliwa, P., Rataj, K., Kafel, R., and Bojarski, A.J. (2018). Salt Bridge in Ligand-Protein Complexes-Systematic Theoretical and Statistical Investigations. *J Chem Inf Model* 58, 2224-2238. 10.1021/acs.jcim.8b00266.
 57. Ferreira de Freitas, R., and Schapira, M. (2017). A systematic analysis of atomic protein-ligand interactions in the PDB. *Medchemcomm* 8, 1970-1981. 10.1039/c7md00381a.
 58. Peng, Y.H., Shiao, H.Y., Tu, C.H., Liu, P.M., Hsu, J.T., Amancha, P.K., Wu, J.S., Coumar, M.S., Chen, C.H., Wang, S.Y., et al. (2013). Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors. *J Med Chem* 56, 3889-3903. 10.1021/jm400072p.
 59. Gomez, J.A., Gama, V., Yoshida, T., Sun, W., Hayes, P., Leskov, K., Boothman, D., and Matsuyama, S. (2007). Bax-inhibiting peptides derived from Ku70 and cell-penetrating pentapeptides. *Biochem Soc Trans* 35, 797-801. 10.1042/bst0350797.
 60. Copeland, R.A., Lombardo, D., Giannaras, J., and Decicco, C.P. (1995). Estimating KI values for tight binding inhibitors from dose-response plots. *Bioorg Med Chem Lett* 5, 1947-1952. 10.1016/0960-894X(95)00330-V.
 61. Johnson, D.R., Bhatnagar, R.S., Knoll, L.J., and Gordon, J.I. (1994). Genetic and biochemical studies of protein N-myristoylation. *Annu Rev Biochem* 63, 869-914. 10.1146/annurev.bi.63.070194.004253.
 62. Monassa, P., Rivière, F., Dian, C., Frotin, F., Giglione, C., and Meinnel, T. (2023). Biochemical and structural analysis of N-myristoyltransferase mediated protein tagging. *Methods Enzymol* 684, 135-166. 10.1016/bs.mie.2023.02.016.
 63. Kabsch, W. (1993). Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. *J Appl Crystallogr* 26, 795-800. 10.1107/S0021889893005588.
 64. Evans, P.R., and Murshudov, G.N. (2013). How good are my data and what is the resolution? *Acta Crystallogr D Biol Crystallogr* 69, 1204-1214. 10.1107/S0907444913000061.
 65. Vagin, A., and Teplyakov, A. (1997). MOLREP: an automated program for molecular replacement. *J. Appl. Cryst.* 30, 1022-1225. 10.1107/S0907444909042589.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66. Murshudov, G.N., Skubak, P., Lebedev, A.A., Pannu, N.S., Steiner, R.A., Nicholls, R.A., Winn, M.D., Long, F., and Vagin, A.A. (2011). REFMAC5 for the refinement of macromolecular crystal structures. *Acta Crystallogr D Biol Crystallogr* *67*, 355-367. 10.1107/S0907444911001314.
 67. Adams, P.D., Afonine, P.V., Bunkoczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., Hung, L.W., Kapral, G.J., Grosse-Kunstleve, R.W., et al. (2010). PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr* *66*, 213-221. 10.1107/S0907444909052925.
 68. Emsley, P., Lohkamp, B., Scott, W.G., and Cowtan, K. (2010). Features and development of Coot. *Acta Crystallogr D Biol Crystallogr* *66*, 486-501. 10.1107/S0907444910007493.
 69. Schuttelkopf, A.W., and van Aalten, D.M. (2004). PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. *Acta Crystallographica Section D* *60*, 1355-1363. 10.1107/S0907444904011679.
 70. Chen, V.B., Arendall, W.B., 3rd, Headd, J.J., Keedy, D.A., Immormino, R.M., Kapral, G.J., Murray, L.W., Richardson, J.S., and Richardson, D.C. (2010). MolProbity: all-atom structure validation for macromolecular crystallography. *Acta Crystallogr D Biol Crystallogr* *66*, 12-21. 10.1107/S0907444909042073.
 71. Liebschner, D., Afonine, P.V., Moriarty, N.W., Poon, B.K., Sobolev, O.V., Terwilliger, T.C., and Adams, P.D. (2017). Polder maps: improving OMIT maps by excluding bulk solvent. *Acta Crystallogr D Struct Biol* *73*, 148-157. 10.1107/s2059798316018210.
 72. Laskowski, R.A., and Swindells, M.B. (2011). LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. *J Chem Inf Model* *51*, 2778-2786. 10.1021/ci200227u.
 73. Boisson, B., and Meinnel, T. (2003). A continuous assay of myristoyl-CoA:protein N-myristoyltransferase for proteomic analysis. *Anal Biochem* *322*, 116-123. 10.1016/j.ab.2003.07.007.
 74. Rivière, F., Monassa, P., Giglione, C., and Meinnel, T. (2023). Kinetic and catalytic features of N-myristoyltransferases. *Methods Enzymol* *684*, 167-190. 10.1016/bs.mie.2023.02.018.
 75. Fieulaine, S., Boularot, A., Artaud, I., Desmadril, M., Dardel, F., Meinnel, T., and Giglione, C. (2011). Trapping conformational states along ligand-binding dynamics of

peptide deformylase: the impact of induced fit on enzyme catalysis. PLoS Biol 9,
e1001066. 10.1371/journal.pbio.1001066.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1







Figure 2









Figure 3







Figure 4






Figure 5

a



b







Figure 6

Figure 7






Figure 7